DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Beepen-VK (Penicillin V Potassium) - Summary

 
 



BEEPEN-VK SUMMARY

BEEPEN-VK®
brand of
penicillin V potassium
tablets and oral solution

Beepen-VK (penicillin V potassium) is the potassium salt of penicillin V.

Beepen-VK is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:

Streptococcal infections—mild to moderately severe—of the upper respiratory tract and including scarlet fever and erysipelas.

Pneumococcal infections—mild to moderately severe—of the respiratory tract, including otitis media.

Staphylococcal infections—mild infections of skin and soft tissue (culture and sensitivity tests should be performed).

Fusospirochetosis (Vincent’s infection) of the oropharynx—mild to moderately severe infections.

For prevention of recurrence following rheumatic fever and/or chorea.

Note: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis and arthritis should not be treated with oral penicillins during the acute stage.

Indicated surgical procedures should be performed.

The following infections will usually respond to adequate doses of penicillin V: Streptococcal infections (without bacteremia)—Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas.

Note: Streptococci in Groups A, C, G, H, L and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections—Mild to moderately severe infections of the respiratory tract.

Staphylococcal infections (penicillin G-sensitive)—Mild infections of the skin and soft tissue.

Note: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections.

Fusospirochetosis (Vincent’s gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Note: Necessary dental care should be accomplished in infections involving the gum tissue.

Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea. Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions.


See all Beepen-VK indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Beepen-VK (Penicillin V)

Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. [2008.06]
BACKGROUND: Rheumatic fever is a preventable chronic disease preceded by group A beta-haemolytic streptococcal (GABHS) pharyngitis. OBJECTIVE: To test the non-inferiority of once-daily (QD) oral amoxicillin to the recommended twice-daily (BID) oral penicillin V in GABHS pharyngitis... CONCLUSION: In this adequately powered study, once-daily oral amoxicillin is not inferior to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis.

Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. [2007.12]
CONCLUSION: Since the 90% CI for AUC0-t, AUC0-infinity and Cmax ratios were all within the 80 - 125% interval proposed by the US FDA and accepted by ANVISA, it was concluded that the Meracilina formulation (manufactured by AchA(c) S.A.) is bioequivalent to Pen-Ve-Oral (manufactured by Eurofarma) for both the rate and the extent of bioavailability.

Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16. [2007.09]
OBJECTIVE: To study the clinical recovery from acute otitis media (AOM) in children, 2-16 years of age, managed with or without treatment with phenoxymethylpenicillin (PcV)... CONCLUSIONS: Our investigation supports that PcV treatment of AOM does not affect the recovery time or complication rates. PcV provided some symptomatic benefit in the treatment of AOM in otherwise healthy children, aged 2-16 years.

A randomized prospective controlled trial of antibiotic prophylaxis in intraoral bone-grafting procedures: preoperative single-dose penicillin versus preoperative single-dose clindamycin. [2006.05]
In this comparative study, 150 consecutive patients undergoing local intraoral bone grafting randomly received either an oral single dose of 600 mg clindamycin or 2 g of the penicillin phenethicillin 1 h before incision. Primary endpoint was wound infection at the receptor site within 8 weeks of surgery...

Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. [2006]
BACKGROUND: A longer duration treatment is preferred in erythema migrans (EM) to prevent late complaints. OBJECTIVES: To determine whether 20 (20d-pt) or 14 days (14d-pt) of phenoxymethylpenicillin (PenV) have similar efficacy in treating EM and preventing further sequelae... CONCLUSION: A 2-week treatment regimen of PenV seems to be as effective as a 3-week course with no statistical differences for clinical and serological findings after treatment. Copyright (c) 2006 S. Karger AG, Basel.

more studies >>

Clinical Trials Related to Beepen-VK (Penicillin V)

APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat [Completed]

TELI TON - Telithromycin in Tonsillitis [Terminated]
This is a multinational, randomized (1: 1), double blind, double dummy, comparator-controlled, 2 parallel treatment group study in subjects from 6 months to < 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P).Each subject will receive either telithromycin 25 mg/kg once daily for 5 days or penicillin V, 13. 3 mg/kg three times daily for 10 days. Matching placebo for telithromycin and penicillin V will also be dispensed for 5 and 10 days respectively, to provide blinding to the different treatment regimens. A positive rapid identification test for streptococcal Group A antigen will be required for all subjects at Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture, identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults [Terminated]
This is a multinational, randomized (1: 1), double blind, comparator-controlled, 2 parallel treatment group study in subjects equal to or over 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400 mg over-encapsulated tablets, 800 mg once daily for 5 days or penicillin V 250 mg over-encapsulated tablets, 500 mg three times daily for 10days. Matching placebo capsules will be dispensed to maintain the blind between the treatment groups. A positive rapid identification test for streptococcal Group A antigen will be required for all subjects at Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture, identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat [Completed]

APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat [Completed]
The purpose of the this study is to evaluate the safety of efficacy of APC-111 775 mg MP tablet once daily dosing for 7 days for treating patients with strep throat. The evaluation will look to confirm if APC-111 eliminates the bacterial infection (Streptococcus pyogenes).

more trials >>


Page last updated: 2008-06-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014